• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Which Markers Can We Use to Screen for Early and Late Preeclampsia?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Recent studies indicate that predictive models can be used to identify women at risk for preeclampsia
  • Aspirin appears to prevent preeclampsia and can be integrated into screening programs
  • Sonek et al. (AJOG, 2017) determined the feasibility of first trimester screening for preeclampsia, including maternal characteristics, medical history, biomarkers, and placental volume

METHODS:

  • Prospective observational nonintervention cohort study
  • Inclusion: Patients who presented for an ultrasound examination between 11w0d-13w6d weeks’ gestation
  • Risk of preeclampsia was calculated based on maternal characteristics, mean maternal arterial blood pressure at intake (MAP) maternal biomarkers, and estimated placental volume
  • Ultrasound measurements included
    • Transabdominal Doppler measurement of the uterine artery pulsatility index (UtA-PI)
    • Estimated placental volume (EPV), using maximal width, height and thickness measurements
  • Serum Biomarkers: (PAPP)-A, placental growth factor (PlGF), and maternal serum alpha-fetoprotein (MSAFP)
  • Primary outome: preeclampsia with subsequent delivery either early (<34 weeks’ gestation) or late (≥34 weeks’ gestation)

RESULTS:

  • 1068 patients were analyzed
    • 4.3% developed preeclampsia: 1.22% with early delivery <34 weeks, and 3.09% with delivery ≥34 weeks
  • Using maternal characteristics, serum biomarkers and UtA-PI, the detection rate of early-onset preeclampsia was 85% with a 5% false positive rate
  • With the same protocol, the detection rates for preeclampsia with delivery <37 weeks were 52% (5% false positive rate) and 60% (10% false-positive rate)
  • Based on maternal characteristics, the detection rates for late-onset preeclampsia ≥34 weeks were 15% (5% false positive rate) and 48% (10% false positive rate), while for preeclampsia at ≥37 weeks’ gestation the detection rates were 24% and 43%, respectively
  • The addition of biomarkers did not improve detection rates for late-onset preeclampsia and preeclampsia with delivery at >37 weeks’ gestation

CONCLUSION:

  • Screening for preeclampsia at 11w0d-13w6d gestation using maternal characteristics and biomarkers is associated with a high detection rate for a low false-positive rate
    • MSAFP contributed to detection
  • Screening for late-onset preeclampsia screening yields poorer results
  • The addition of placental volume and mean arterial pressure was of limited benefit, however, and may be due to small sample size
    • MAP and PlGF have been shown to helpful in other studies and EPV (which tended to ward being smaller in this study) may still be shown to be of benefit in larger data sets
  • This study was undertaken in the US, where testing is less centralized and ethnic and medical histories may differ from the UK
  • The authors conclude that based on results which are consistent with previous studies such as the ASPRE trial, a first trimester screening program can detect those at risk of early onset preeclampsia

Learn More – Primary Sources:

First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Aspirin Treatment for Women at Risk for Preeclampsia – ACOG, SMFM and USPSTF Recommendations
ASPRE Trial: A Combined Risk Algorithm and Use of Aspirin to Prevent Preterm Preeclampsia
Does Carrying a Fetus with a Congenital Heart Defect Increase Preeclampsia Risk?
Are Vitamin D Levels Linked to Preeclampsia and Preterm Birth?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site